Navigation Links
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Date:1/25/2013

DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole , president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."

NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). OSENI, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.

The most common adverse events (greater than or equal to 4%) reported with NESINA include nasopharyngitis, headache and upper respiratory tract infection. With regard to OSENI, common adverse events (greater than or equal to 4%) reported include nasopharyngitis, back pain and upper respiratory tract infection. Common adverse events (greater than or equal to 4%) re
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
2. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
3. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
4. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
5. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
6. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
7. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
8. Zimmer Receives FDA Clearance for Revolutionary New Surgical Guidance Technology
9. American Capital Receives $60 Million From The Sale Of Lifoam Holdings And Generates An 11% Return On Its Investment
10. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
11. Brolex C SAFE cesarean section safety device receives top scores, rated a MUST HAVE medical device for performing c/sections.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- Delivery of the ... is placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... and in-depth market survey on Global and Chinese ... basic information of Hemodialysis Machine including its classification, ... global and China,s top manufacturers of Hemodialysis Machine ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... 2011 Bluestar Silicones is moving forward with ... S.C., where it will establish its new manufacturing footprint and ... relocate its two U.S. manufacturing facilities currently in Ventura, Calif., ... set on 20 acres in York.   "The ...
... 5, 2011 Since its inception in 2007, ... has grown each year, and this year’s conference ... AdvaMed 2011 was up nearly 12 ... meetings climbed 21 percent. The fifth annual conference ...
Cached Medicine Technology:Bluestar Silicones Moves Forward with Growth Plans; Completes Acquisition of Facility in South Carolina 2Annual AdvaMed MedTech Conference Continues Impressive Growth 2Annual AdvaMed MedTech Conference Continues Impressive Growth 3
(Date:7/24/2014)... A new study led by the Translational Genomics Research ... viruses and the immune system during HIV infection. , ... to infect others based on their blood viral ... in their semen despite having low levels in their ... the virus can be found in different parts of ...
(Date:7/24/2014)... 24, 2014 Memantine was initially developed by ... in Germany under the brand name Akatinol; it was later ... Ebixa and in the USA to Forest Labs as Namenda. ... in 2013. In the US, Forest reported Namenda sales of ... in Canada, Australia and the European region has increased the ...
(Date:7/24/2014)... Members of the Iowa State Board of Health voted ... Sales at OutcomesMTM, as their Chairperson. Wolnerman said he is ... that his peers chose to keep him in this leadership ... can for the citizens of Iowa,” Wolnerman said. “As a ... special insight to concerns and issues related to the health ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 In a recent ... States has officially put an end to criminal penalties associated ... a new era for marijuana reform in Washington DC, giving ... The new law replaces criminal penalties for possession of one ... selling and the possession of more than an ounce of ...
(Date:7/24/2014)... Vaccination (HPV) even after becoming sexually active had ... those who were never vaccinated. These findings appear ... , Researchers from Boston University School of ... cross-sectional study of 235 women age 21 to ... and demographic and behavioral characteristics were self-reported and ...
Breaking Medicine News(10 mins):Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Washington D.C. Decriminalizes Marijuana 2
... IDXX ), announced today that it will participate ... Chairman,President and CEO, is scheduled to make a presentation ... a.m. (PT), at the Westin St. Francis Hotel,San Francisco, ... presentation through a link on the home page of ...
... 5 Million People in Over 80 Countries Who Are ... What began in a,modest Missouri church has exploded into ... for 2008. People are giving up complaining,and their health, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071219/DC10329LOGO ), "It,s a very ...
... Pelosi,issued the following statement today on House passage of ... bill, which extends SCHIP,through March 31, 2009 and provides ... be dropped from their coverage, will now,be sent to ... President Bush and a small Republican minority in the ...
... firm will introduce NutreStore(TM) in spring 2008, ... Medical, Inc., a,Torrance, California based pharmaceutical company, ... exclusive sublicense agreement with Cato BioVentures of,Research ... protected drug,NutreStore(TM) brand L-Glutamine. Under this agreement, ...
... Dec. 19 In 1991, Kharma Amos,dressed up ... materials in Tulsa, OK., (Photo: http://www.newscom.com/cgi-bin/prnh/20071219/DC10343-a ... same year, 16-year-old Joshua Love began volunteering for ... in Santa,Fe, NM. He wanted to combat homophobia ...
... 2007) -- In recognition of his distinguished contributions in ... Cornell Medical Center has been selected by the American ... Bruce Memorial Award, one of 17 awards in internal ... place on May 15, 2008, at the annual meeting ...
Cached Medicine News:Health News:A 'Happy New You' in the New Year 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth 2Health News:A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth 3Health News:Dr. Lewis Drusin receives American College of Physicians James D. Bruce Memorial Award 2
... Designed to fully integrate the ... clinical laboratory working under regulatory ... uses five core modules to ... and create an environment of ...
... Fully automated chemiluminescence assay ... growth hormone in serum. Growth ... hormone secreted by the anterior ... of hypothalamic growth hormone releasing ...
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
Inquire...
Medicine Products: